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Results: Early-onset patients were more likely to be amyloid positive. Change in diagnosis was
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 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Appropriate use criteria (AUC); Positron emission tomography (PET); Amyloid; Alzheimer’s disease (AD); Mildcognitive impairment (MCI)1. Introduction accuracy of clinical diagnosis compared to the gold standardAlzheimer’s disease (AD) is the most common neurode-
generative disorder and the sixth most common cause of
death in the United States [1]. A recent evaluation of theuthor. Tel.: 11-317-963-7173; Fax: 11-317-963-
postol@iu.edu
16/j.dadm.2016.12.001
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).(postmortem observations) demonstrated that dementia ex-
perts show only modest accuracy when diagnosing AD,
with sensitivity ranging from 71% to 87% and specificity
ranging from 44% to 71% [2]. Several dementing disor-
ders—hippocampal sclerosis, frontotemporal, Lewy body,
vascular, and tangle-only dementia—were commonly
mistaken for AD dementia. Among cases thought to harbor
non-AD pathology, 39% showed histopathology meeting or
exceeding the AD pathologic threshold [2].imer’s Association. This is an open access article under the CC BY-NC-ND
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clinicians perceive AD in terms of clinical staging and pathol-
ogy progression. Two significant advances—the positron
emission tomography (PET) ligandswith high affinity for am-
yloid plaques [3] and neurofibrillary tangles [4]—enable us to
visualize AD pathology in vivo. Three amyloid PET imaging
compounds are now Food and Drug Administration (FDA)
approved and available for clinical use [5–10]. A recent
meta-analysis [11] reviewed the diagnostic performance of
F18-florbetapir, and F18-florbetaben. Fourteen of the 16 arti-
cles included only cognitively normal (mean Mini-Mental
State Examination [MMSE] score 5 29.3) or dementia sub-
jects (mean MMSE 5 21.3). The two compounds demon-
strated 89.6% and 89.3% sensitivity, 87.2% and 87.6%
specificity, and odds ratios of 91.7 and 69.9, respectively
[11]. Regardless, amyloid PET has not become an integral
part of routine clinical care as Medicare and most other insur-
ance carriers do not cover it. The major drawbacks cited by
insurance carriers are (1) imperfect specificity [2], (2) ethical
concern that cognitively normal individualsmight be inappro-
priately scanned (i.e., there are no disease-modifying thera-
pies available for intervention in this group), and (3) the
lack of demonstrated cost-effectiveness [12].
In response to these concerns, the Alzheimer’s Associa-
tion and the Society of Nuclear Medicine and Molecular Im-
aging convened the Amyloid Imaging Task Force (AIT), a
group of imaging and dementia specialists, to establish a
set of recommendations for which patients and in which
clinical scenarios amyloid PET is most appropriate
[13,14]. The experts recognized that widespread diagnostic
use of amyloid PET was not yet justified or feasible, but
that the scan could result in clinical benefit when ordered
by experts in specific clinical scenarios. In these
Appropriate Use Criteria (AUC), experts outlined three
clinical indications for the diagnostic use of amyloid PET
imaging: (1) patients with progressive mild cognitive
impairment (MCI) in which clinical uncertainty exists and
the patient would benefit from greater certainty; (2)
patients with dementia syndrome suggestive of AD, but
with an atypical presentation or suspected mixed etiology;
and (3) patients with early-onset progressive cognitive
decline. These criteria are based on the evidence that approx-
imately 40% to 60% of patients with amnestic MCI and 10%
to 20% of clinically diagnosed AD dementia patients fail to
show amyloid pathology on PET [15].
Another important guideline of the AUC for amyloid PET
imaging is the recommendation that the responsibility for
determining patients’ eligibility should liewithmedical profes-
sionals who have significant expertise in evaluating and treat-
ing patients with dementia defined as 25% or greater
proportion of clinical practice devoted to cognitive disorders
of the elderly [13]. This recommendation is based on the fact
that for a diagnosis of dementia or MCI of the AD type to be
established, the evaluating physician has to interpret and care-
fully consider the complex information contained in several
critical parts of the workup, including the clinical andneuropsychological examinations, the laboratory workup,
and structural and amyloid PET imaging. A final deliberation
on disease stage (cognitively normal vs. MCI vs. dementia)
and the presumed etiology can only be concluded after such
thorough workup has been completed. Thus significant exper-
tise and experience are deemed necessary.
Last, the committee recommended that amyloid PET
scans be administered only when the scan results are ex-
pected to alter clinical management [13,14].
Given the lack of disease-modifying drugs for AD, the
rationale for using amyloid PET imaging in diagnostic
settings is to help with diagnostic and therapeutic
decision-making and to improve health outcomes by coun-
seling patients and families on diagnosis, prognosis, patient
safety, and legal and financial issues. To date, only a few
studies have investigated the impact of amyloid PET on
patient diagnosis and management.
Grundman et al. [16] analyzed a data set consisting of 113
amyloid-positive and 116 amyloid-negative patients (some
with objective cognitive decline and others with only cogni-
tive complaints without objective cognitive decline). Sub-
jects were recruited as part of a research study aiming to
establish the impact of amyloid imaging in a much broader
clinical population. All study physicians had previous
experience in AD research and 52% had fellowship training
in dementia. The AUC were retrofitted to determine whether
the participants met the AIT recommendations (N5 125) or
not (N 5 104). The study revealed that diagnostic changes
occurred in 55% of all cases. There was a 22% increase in
physicians’ diagnostic confidence after amyloid PET. Physi-
cians made changes to their therapeutic plan in 88% of AUC-
consistent and 86% of the AUC-inconsistent patients
(P 5 .69). The use of cholinesterase inhibitors and meman-
tine increased by 17% in amyloid-positive patients and
decreased by 23% in amyloid-negative patients.
Ossenkoppele et al. [17] scanned a mix of early- and late-
onset patients recruited from the outpatient clinics of the VU
Medical Center in the Netherlands with Pittsburgh compound
B. The authors reported 23% change in diagnosis and increase
of diagnostic certainty for 71% to 81% after amyloid PET.
Zwan et al. [18] recently presented data regarding the
benefits of amyloid PET in early-onset dementia which
they defined as age of onset,70 years. Amyloid PET scans
resulted in diagnostic change in 20% of the amyloid-positive
cases and physicians’ confidence in their clinical diagnosis
increased from 76% to 90%.
Dell’Agnello et al. [19] reported that 47% of their AUC-
consistent patients were amyloid positive compared
with 62% of those who failed to meet the AUC recommen-
dations. After a negative scan, the discontinuation rates of
AD-targeting drugs were 20% among those who met the
criteria versus 33% among those who did not.
Bensa€ıdane et al. [20] looked at 28 patients with an atyp-
ical dementia syndrome, 14 of which were amyloid positive
and 14 amyloid negative. They reported diagnostic changes
in 32.1% (17.8% changed from AD to non-AD, 14.3% from
L.G. Apostolova et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 5 (2016) 15-22 17non-AD to AD diagnosis). They also reported a 44% in-
crease in diagnostic confidence. Altered management
occurred in 71.4% of cases.
Boccardi et al. [21] recently presented data from a large
cohort recruited from outpatient clinics for an amyloid
PET research study. The final cohort consisted of 126 pa-
tients meeting AUC and 21 who did not. Diagnostic changes
occurred in 25% of AUC-consistent patients and 29% of
AUC-inconsistent patients (P 5 .79). Therapeutic changes
occurred in 33% versus 29% of the AUC-consistent versus
inconsistent patients (P 5 .81).
While these studies seem to indicate that the amyloid
PET scanning improves diagnostic accuracy, increases diag-
nostic certainty, and results in therapeutic changes, all but
one [18] used convenience research cohorts who were re-
cruited for other research studies. The study by Zwan et al.
[18] focused solely on early-onset cases, though with a
higher than conventional age cutoff. The present analysis
is the first to examine an actual clinical population with pa-
tients from broad age range, as they were consecutively eval-
uated in a tertiary medical center. The purpose of our work
was to examine the utility of the AUC for amyloid imaging
using a case series approach.2. Methods
2.1. Patient sample
Our data set consisted of all patients who received amy-
loid PET imaging with F18-florbetapir for diagnostic pur-
poses at University of California Los Angeles (UCLA)
before December 2014 (N 5 53). Twenty-eight of the cases
were documented to have experienced cognitive decline af-
ter the age of 65 years (late onset) while 24 started declining
before 65 years of age (early onset). Age of symptom onset
was not documented in the chart for one case presenting at
age 67 years with dementia syndrome and Mini-Mental
State Examination (MMSE) score of 24. Forty-eight patients
were evaluated by dementia experts. Of these, 35 met AUC.
The 23 AUC-consistent early-onset cases, (AUC-consistent
by definition - third criterion outlined above in
Introduction), had the following pre-PET diagnoses: 11
AD, 6 primary progressive aphasia (PPA), 3 posterior
cortical atrophy, 2 MCI, and 1 behavioral variant frontotem-
poral dementia (FTD) versus frontal-variant AD. Among the
25 late-onset cases, 12 were AUC-consistent and had pre-
PET diagnoses of atypical AD (N 5 6), MCI (N 5 2),
PPA (N 5 3), and mixed dementia (N 5 1). Of the 13
late-onset AUC-inconsistent cases, seven were thought to
have dementia due to AD (two with logopenic progressive
aphasia variant) and six with MCI due to AD.
The amyloid PET scans for the remaining five patients
were ordered by UCLA stroke neurologists who did not
meet criteria as dementia experts as proposed by the AUC.
Three of these cases presented with lobar hemorrhages
thought to be due to underlying cerebral amyloidangiopathy (CAA). One was diagnosed with dementia of un-
determined etiology and one with MCI thought to be due to
AD-type pathology. Of the same five patients, one experi-
enced early onset of cognitive decline at the age of 47 years
while the remainder had late onset (age of onset range 74–
93 years). All five cases met the rest of the AUC and were
grouped in the AUC-consistent group. As the ordering neu-
rologists were not dementia experts, we also reran all ana-
lyses excluding these cases.
For the purposes of this study, post-PET therapeutic
changes were defined as follows: (1) medications discontin-
ued after amyloid-negative scan (N 5 6) and (2) AD drugs
such as cholinesterase inhibitors, memantine, or both started
after the results of the PET scan (N 5 27). The following
were coded as no therapeutic changes as a result of the
PET scan: (1) no medications were started (N5 5), (2) med-
ications were not changed (N 5 12), (3) medications were
only titrated up but not initiated (N 5 2). One case was
lost to follow-up because of insurance coverage changes,
and the medical chart did not indicate whether medications
were instituted. This patient was excluded from the analyses
of therapeutic changes.
2.2. F18-florbetapir PET acquisition and interpretation
All patients were referred for F18-florbetapir PET evalua-
tion by the Nuclear Medicine Department of UCLA. All
scans followed the FDA-approved F18-florbetapir adminis-
tration protocol and were clinically read by amyloid imag-
ing–trained board-certified nuclear medicine physicians.
We analyzed all F18-florbetapir scans with NeuroQ, an
FDA-cleared software for PET image visualization and
interpretation, to evaluate how quantitative interpretation
of data compares with clinical reads. After correction for
tissue-based attenuation, NeuroQ automatically measures
the number of radioactive events emitted from each pixel
and normalizes these measurements using whole cerebellum
as a reference. The program then computes the mean stan-
dard uptake volume ratios (SUVRs) based on the Clark
method [6] and derives a final mean SUVR value for each
subject. Mean SUVR1.17 was used as the quantitative cut-
off for amyloid positivity [22].
2.3. Statistical methods
We assigned patients to groups based on age of symptom
onset and consistency with the AUC. We used Student t test
and chi-square statistics to compare demographic variables
between groups and chi-square statistics to compare the
rate of diagnostic and treatment change between groups.3. Results
3.1. Early-onset versus late-onset comparisons
Subjects were classified based on age of onset
(cutoff set at 65 years) as early onset (N5 24, age of onset
Table 1
Early-onset versus late-onset group characteristics
Variable Early onset, N 5 24 Late onset, N 5 28 P-value
Age at disease onset, y 54.5 (5.7) 75.1 (5.6) ,.0001
Age at scan, y 58.9 (4.9) 79.4 (5.7) ,.0001
Disease duration 3.8 (2.9) 4.1 (2.4) .7
Education, y 16.2 (2.2) 16.0 (2.7) .8
Sex, M/F 9/15 14/14 .4
Positive family history, % 46 29 .2
New patient, % 50 53 .8
Positive amyloid PET read, % 80 57 .016
Mean SUVR 1.42 (0.28) 1.35 (0.31) .4
SUVR . 1.17, % 88 61 .03
Change in diagnosis, % 17 43 .041
Change in therapy, % 79 59 .13
Abbreviations: PET, positron emission tomography; SUVR, standard uptake volume ratio.
NOTE. Bold text indicates significant P value.
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onset  65 years). Age of symptom onset was not docu-
mented in the chart for one case presenting at age 67 years
with dementia syndrome and MMSE score of 24. Within
the late-onset group, 15 cases were AUC-consistent and
13 AUC-inconsistent. Quantitative F18-florbetapir ana-
lyses revealed one positive clinical read with mean
SUVR of 0.94 and five negative clinical reads with
mean SUVRs ranging between 1.30 and 1.44. All scans
with disagreement between clinical and quantitative-
based assignments occurred in late-onset cases.Table 2
Diagnostic changes in the early-onset group
Case no. Pre-PET diagnosis Post-PET diag
Cases with change in diagnosis
EO1 PPA due to AD PPA due to FT
EO2 PPA due to FTD PPA due to AD
EO3 FTD Frontal variant
EO4 MCI due to AD Hippocampal s
Cases without change in diagnosis
EO5 AD dementia
EO6 AD dementia
EO7 AD dementia
EO8 AD dementia
EO9 AD dementia
EO10 AD dementia
EO11 AD dementia
EO12 AD dementia
EO13 AD dementia
EO14 AD dementia
EO15 AD dementia
EO16 MCI due to AD
EO17 PCA due to AD (MCI stage)
EO18 PCA due to AD
EO19 PCA due to AD
EO20 PPA due to AD
EO21 PPA due to AD
EO22 PPA due to AD
EO23 PPA due to FTD
EO24 CAA due to AD
Abbreviations: PET, positron emission tomography; SUVR, standard uptake vo
negative; pos, positive; MCI, mild cognitive impairment; PCA, posterior cortical aThere were no differences in sex, education, disease dura-
tion, and family history of dementia or proportion of new vs.
established patients between early- and late-onset cases. As
expected, early-onset cases were significantly younger at the
time of symptom onset and at the time of scan (P, .0001 for
both). A significantly greater proportion of early-onset
compared with late-onset cases was amyloid positive (visual
read 88% vs. 57%, P 5 .016, quantitative analyses 88% vs.
61%, P 5 .03; Table 1).
We observed significantly greater frequency of diagnostic
change in late-onset compared with early-onset casesnosis (if different) SUVR Visual read
D 0.815 neg
1.624 pos
AD 1.445 pos
clerosis 0.616 neg
1.315 pos
1.310 pos
1.531 pos
1.305 pos
1.358 pos
1.423 pos
1.470 pos
1.312 pos
1.696 pos
1.598 pos
1.655 pos
1.504 pos
1.476 pos
1.526 pos
1.591 pos
1.639 pos
1.773 pos
1.772 pos
1.054 neg
1.338 pos
lume ratio; PPA, primary progressive aphasia; AD, Alzheimer disease; neg,
trophy; FTD, frontotemporal dementia; CAA, cerebral amyloid angiopathy.
Table 3
AUC-consistent versus AUC-inconsistent late-onset group characteristics
Variable AUC-consistent, N 5 15 AUC-inconsistent, N 5 13 P-value
Age of disease onset, y 77.0 (5.8) 72.8 (4.6) .049
Age at scan, y 81.6 (6.2) 76.8 (4.0) .025
Disease duration 4.4 (2.8) 3.8 (2.0) .5
Education, y 16.3 (2.4) 15.7 (3.1) .6
Sex, M/F 7/8 7/6 .7
Positive family history, % 20 39 .3
New patient, % 47 62 .4
Positive amyloid PET read, % 47 69 .2
Mean SUVR 1.35 (0.36) 1.35 (0.26) .98
SUVR . 1.17, % 60 77 .3
Change in diagnosis, % 53 23 .1
Change in therapy, % 43 77 .072
Abbreviations: AUC, Appropriate Use Criteria; PET, positron emission tomography; SUVR, standard uptake volume ratio.
NOTE. Bold text indicates significant P value. Italicized text indicates trending P value.
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therapeutic changes in the early-onset cases (48% vs. 79%,
P 5 .022). The results remained largely unchanged when
we excluded the non–dementia experts’ cases (diagnostic
changes 48% vs. 17%, P 5 .069; treatment changes 52%
vs. 83%, P 5 .028). There were a total of four diagnostic
changes in the early-onset group after amyloid PET results
were available (Table 2). Two cases were amyloid positive
and two were amyloid negative.
Among the 21 amyloid-positive early-onset cases, both
acetylcholinesterase inhibitors (AChEIs) and memantine
were initiated in five cases, only AChEIs were initiated in
four cases, and AChEIs were titrated up to therapeutic doses
in another two cases (actual management). Memantine was
added in eight cases and increased in one (actual manage-
ment). Two patients who were already prescribed therapeu-
tic doses of both AChEIs and memantine required noTable 4
Diagnostic changes in the late-onset AUC-consistent group
Case Pre-PET diagnosis Post-P
Cases with change in diagnosis
LO1 Atypical MCI MCI s
LO2 PPA (presumed non-AD)* PPA d
LO3 PPA (presumed non-AD)* PPA d
LO4 AD with CAA No AD
LO5 Atypical MCI (presumed non-AD)* MCI d
LO6 Mixed dementia Vascu
LO7 Vascular cognitive impairment (VCI) Mixed
LO8 Possible AD Deme
Cases without change in diagnosis
LO9 Atypical MCI (presumed non-AD - dep
LO10 PPA (presumed non-AD)*
LO11 Atypical MCI (presumed SNAP)
LO12 Atypical AD
LO13 Atypical AD
LO14 CAA due to AD
LO15 DLB
Abbreviations: AUC, Appropriate Use Criteria; PET, positron emission tomogra
pos, positive; neg, negative; SNAP, suspected non-AD pathophysiology; PPA, prim
bodies; CAA, cerebral amyloid angiopathy.
*Physician-suspected non-AD pathology (with AD in the differential diagnosisadditional therapeutic intervention. In one case of amyloid
angiopathy with a positive amyloid PET scan, the physician
(a non–dementia expert) did not recommend any therapy.
Dementia experts discontinued memantine in two of the
three amyloid-negative early-onset cases. The third
amyloid-negative case was already on donepezil when first
evaluated but could not follow up with a dementia expert
at UCLA due to change in insurance. Whether his/her
outside physician discontinued donepezil in response to
the results from the scan was not documented. This case
was excluded from our treatment change analyses.3.2. AUC-based comparisons within the late-onset group
The AUC-inconsistent patients were significantly
younger at disease onset and at the time of PET compared
with the AUC-consistent group (Table 3). There were noET diagnosis (if different) SUVR Visual read
econdary to SNAP/anxiety 1.061 neg
ue to AD 1.368 pos
ue to AD 1.637 pos
pathology 1.144 neg
ue to AD 2.002 pos
lar dementia 0.874 neg
VCI and AD 1.291 pos
ntia due to drug abuse 0.916 neg
ression)* 1.429 neg
1.120 neg
0.998 neg
1.431 pos
2.050 pos
1.508 pos
1.444 neg
phy; SUVR, standard uptake volume ratio; MCI, mild cognitive impairment;
ary progressive aphasia; AD, Alzheimer disease; DLB, dementia with Lewy
).
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tory of dementia, proportion of new versus established pa-
tients, mean SUVR, and proportion of amyloid positive by
visual read or quantitative determination between late-
onset AUC-consistent and AUC-inconsistent cases
(Table 3).
There were a total of eight diagnostic changes (53%) in
the AUC-consistent group and three diagnostic changes
(23%) in the AUC-inconsistent group (P 5 .1, Tables 4
and 5).
Interestingly, despite the trend for greater rate of
diagnostic changes in the AUC-consistent group, treatment
changes tended to be more frequent in the AUC-
inconsistent group (62% vs. 36%, P 5 .18). The AUC-
inconsistent cases were more likely to be new patients
relative to AUC-consistent patients, but this difference failed
to reach statistical significance (62% vs. 47%, P 5 .43;
Table 4). The findings remained unchanged after excluding
cases evaluated by non–dementia experts (AUC-inconsistent
67% vs. AUC-consistent 36%, P 5 .15).3.3. Discrepant visual versus quantitative amyloid PET
results
One of the positive clinical reads with normal SUVR
(SUVR 5 0.94) was in a patient who was already on done-
pezil. No changes were made after the scan as the visual
interpretation supported the treatment. The SUVR was esti-
mated later in the context of this publication at a time when
the patient was no longer under the care of the dementia
specialist.
There were five negative clinical reads with SUVR in the
positive range (1.30–1.44). In three of these cases, the de-
mentia expert strongly suspected false-negative reads and
increased donepezil to therapeutic dose in one and added
memantine in two. In the remaining two cases, the dementia
expert discontinued donepezil. The physician initiallyTable 5
Diagnostic changes in the late-onset AUC-inconsistent group
Case no. Pre-PET diagnosis Post-PET diag
Cases with change in diagnosis
LO16 Probable AD SNAP
LO17 Probable AD SNAP
LO18 MCI due to AD MCI secondary
Cases without change in diagnosis
LO19 MCI due to AD
LO20 MCI due to AD
LO21 MCI due to AD
LO22 MCI due to AD
LO23 MCI due to AD
LO24 Probable AD
LO25 Probable AD
LO26 Probable AD
LO27 Probable AD
LO28 Probable AD vs. DLB
Abbreviations: AUC, Appropriate Use Criteria; PET, positron emission tomogr
suspected non-AD pathophysiology; pos, positive; neg, negative; MCI, mild cogndiscontinued donepezil in the fourth case. After the quanti-
tative analyses showed high SUVR indicative of moderate-
to-severe amyloid plaque pathology, the physician restarted
donepezil and added memantine later on. The final clinically
interpreted as negative but SUVR-positive case was in
follow-up diagnosed with dementia with Lewy bodies
(DLB), and rivastigmine and later memantine were pre-
scribed.
After careful review of the false-negative and false-
positive scans by two of the senior authors (L.G.A. and
D.H.S.), the misinterpretation of the scans was attributed
to poor scan quality, possible late acquisition, and brain
atrophy.4. Discussion
The AUC were developed to help define a clinical cohort
of patients most likely to benefit from amyloid PET scans
during their diagnostic workup for cognitive decline. The
premises for developing these criteria were both scientific
and economic. Our study is, to our knowledge, the first
outpatient consecutive clinical case series within the United
States that serves to evaluate the utility of the AUC in both
early- and late-onset cases.
The late-onset AUC-consistent cases had high rates of
both diagnostic and treatment changes, strongly arguing
for the value of amyloid imaging for diagnostic refinement
in this cohort. Our early-onset cases showed very high rate
of amyloid positivity and significantly higher rate of thera-
peutic changes compared with the late-onset cases. The
high rate of amyloid positivity could have, at least in part,
been the result of selective referral of cases with high likeli-
hood of AD for amyloid PET imaging. One plausible expla-
nation for the high rate of therapeutic changes could be that
these difficult-to-diagnose cases are often referred drug-
na€ıve by their private practice physicians. Thus we can
conclude that amyloid imaging for these two groups ofnosis (if different) SUVR Visual read
0.941 pos
1.415 neg
to SNAP 0.795 neg
1.335 pos
1.663 pos
1.593 pos
1.577 pos
1.357 neg
1.134 pos
1.504 pos
1.582 pos
1.304 neg
1.401 pos
aphy; SUVR, standard uptake volume ratio; AD, Alzheimer disease; SNAP,
itive impairment; DLB, dementia with Lewy bodies
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derlying etiology and for implementing appropriate thera-
peutic changes.
Patients with cognitive decline in whom the etiology of
AD is deemed to be highly likely are not recommended by
the AIT for amyloid PET scanning as it is thought that
such patients will likely have amyloid pathology. Yet our
data show that amyloid-negative scans are fairly common
in the AUC-inconsistent group, with as many as 23% demon-
strating SUVRs ,1.17. Proportionately, this rate corre-
sponds well to the documented range of diagnostic
sensitivity of 71% to 87% reported in a recent comprehen-
sive analysis of a large data set with postmortem validation
[2]. Given that in all such cases our physicians changed their
diagnostic considerations and treatment plans, one might
conclude that amyloid PETwould also be of value in imag-
ing these subjects.
As we compare our results with those of others, we notice
several agreements and disagreements. We found signifi-
cantly greater amyloid-positive rates among early-onset cases
as opposed to late-onset cases, in agreement with the work of
others [23]. Similar to Dell’Agnello et al. [19], we observed a
greater proportion of amyloid-positive cases among the AUC-
inconsistent group as opposed to the AUC-consistent group
(69% vs. 47% visual read, 77% vs. 60% quantitative read).
One European study [21] reported no difference in
change in diagnosis between the AUC-consistent and
AUC-inconsistent groups and concluded that the AUC do
not have a convincing impact on change in diagnosis. This
is consistent with our results.
The two studies that reported treatment changes were
both done in cohorts recruited for research studies that
involve amyloid PET. The European study [21] reported
low rates of treatment changes that were not significantly
different between the groups (AUC-consistent 33% vs.
AUC-inconsistent 29%, P 5 .81). Similarly, the US study
[16] reported high rates of treatment changes that were not
significantly different between the groups (AUC-consistent
88% vs. AUC-inconsistent 86%, P 5 .9). This twice
observed lack of significance is in agreement with our find-
ings (62% vs. 36%, P 5 .18).
Taken together, our findings and those of others suggest
that more studies with larger patient cohorts are needed to
definitively determine whether amyloid PET information
can result in therapeutic benefits. One such study—the Imag-
ing Dementia—Evidence for Amyloid Scanning (IDEAS)—
is now actively recruiting in the United States. The study pro-
poses to enroll more than 18,000 Medicare beneficiaries with
the goal to ascertain whether the scan changes management
and improves patient-oriented outcomes.
Several strengths and limitations of our work are worth
noting. This is to our knowledge the first outpatient clinical
case series that evaluates the utility of the AUC in both
early- and late-onset cases. This study examined preexist-ing medical records. At the time of all patient evaluations,
our chart review and analyses were not yet planned; hence,
the physicians’ pre- and post-PET diagnostic impressions,
etiological considerations, and treatment plans were
completely unbiased. The major limitation of our study is
the relatively small sample size and the lack of follow-up
for some of the cases. In addition, some otherwise qualified
patients might not have had amyloid PET imaging because
of financial reasons. We do not know whether these pa-
tients would be qualitatively different than the ones we
studied here. The patients seen in our institution cannot
be considered representative of the general population as
they often have higher mean education and socioeconomic
status. Both of these factors have been associated with high
rates of referral to subspecialists and academic memory
clinics. The impact of amyloid PET on the utilization of
additional services such as support groups, counseling,
legal and health care benefit planning, utilization of retire-
ment benefits, etc. by patients and families was not avail-
able for our analyses. Owing to the retrospective nature
of the study, we do not have data on change in physicians’
confidence in diagnosis, their stipulation whether the sub-
ject suspected to have AD has probable versus possible
AD, and any other factors that might affect their
decision-making. In addition, we do not have information
on their apolipoprotein (APOE) genotype, which could
have enriched our discussion as the risk variant APOE ε4
conveys significant risk for presence of brain amyloidosis.
In conclusion, our case series suggests that amyloid imag-
ing information frequently results in both diagnostic and
treatment plan changes. At least in the hands of the dementia
experts who took part in this study, it seems that the benefit for
the early-onset group lies in confirming the presence of
cortical amyloid consistent with a diagnosis of AD, which
prompted the referral for the amyloid PET scan in the first
place, whereas the benefit for the late-onset group lies in iden-
tifying amyloid-negative cases. In both groups, physicians
made therapeutic changes in over two-thirds of the cases.
Our results also suggest that patients who do not fall within
the AUC are perhaps no less likely to benefit from amyloid
imaging than patients meeting AUC. In fact, in a typical clin-
ical series of patients, they may have as a group more to gain
overall from the information that amyloid imaging provides.
Future studies employing large-scale well-designed prospec-
tive clinical protocols will be needed to further clarify the
impact of amyloid PET on patient and family well-being.Acknowledgment
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1. Systematic review: The literature on the utility of
amyloid PET for patient care has been sparse. The
vast majority of published studies report convenience
research cohorts (i.e., recruited for other research
studies). The single outpatient clinical settings’
report focused on early-onset cases. Our study ex-
amines an actual consecutively evaluated outpatient
clinical population with a broad age range.
2. Interpretation: The role of amyloid imaging in the
early-onset group was to confirm the suspected eti-
ology and in the late-onset group to detect amyloid-
negative cases. Patients who do not fall within the
AUC are as likely to benefit from amyloid imaging as
patients who do not. Treatment plan changes
occurred in a substantial majority of the AUC-
inconsistent cases, but only in a minority of the
AUC-consistent cases.
3. Future directions: Large-scale, well-designed pro-
spective clinical studies will be needed to further
clarify the impact of amyloid PET on patient and
family well-being.References
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